Patients with β-thalassemia major have extremely low vitamin D levels, owing to reduced intestinal absorption, subicteric tint, and/or iron-induced higher pigmentation. We investigated whether some polymorphisms within the VDR, CYP24A1, CYP27B1, and GC genes could play a role in deferasirox pharmacokinetics in a cohort of pediatric patients.

Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children

ALLEGRA, SARAH
First
;
CUSATO, JESSICA;DE FRANCIA, SILVIA;LONGO, Filomena;PIRRO, Elisa;MASSANO, DAVIDE;PIGA, Antonio Giulio
Co-last
;
D'AVOLIO, ANTONIO
Co-last
2018

Abstract

Patients with β-thalassemia major have extremely low vitamin D levels, owing to reduced intestinal absorption, subicteric tint, and/or iron-induced higher pigmentation. We investigated whether some polymorphisms within the VDR, CYP24A1, CYP27B1, and GC genes could play a role in deferasirox pharmacokinetics in a cohort of pediatric patients.
28
1
17
22
Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio
File in questo prodotto:
File Dimensione Formato  
01213011-900000000-99221.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 164.78 kB
Formato Adobe PDF
164.78 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1651232
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact